Exchange: Privately held
Chairman and CEO: John O’Malley
HQ: San Antonio, TX
Vericast is reimagining marketing solutions one business-to-human connection at a time. By influencing how over 120 million households eat, shop, buy, save and borrow, Vericast fuels commerce, drives economic growth and directly accelerates revenue potential for thousands of brands and businesses. While its award-winning portfolio of products, technology and solutions are part of the Vericast story, its people are the true differentiators; trailblazers in data intelligence, marketing services, transaction solutions, campaign management and media delivery. For more information, visit www.vericast.com or follow Vericast on LinkedIn.
vTv Therapeutics LLC
President & CEO: Paul Sekhri
HQ: High Point, NC
vTv Therapeutics LLC is a clinical-stage biotechnology company with a pipeline of drug candidates led by TTP399, a potentially transformative treatment for the reduction of hypoglycemic episodes in type 1 diabetes (T1D) patients. vTv announced positive Phase 2 results last year for both of its lead diabetes compounds, TTP273 and TTP399, each of which demonstrated statistically significant reductions in HbA1c. vTv was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration in April 2021 as an oral adjunctive therapy for the treatment of T1D.
SIGA Technologies, Inc.
CEO: Phillip Gomez, Ph.D
HQ: New York, NY
SIGA is a leader in providing solutions for unmet needs in the estimated $10 billion global health security market. In 2018, the U.S. Food and Drug Administration approved SIGA’s first product, oral TPOXX® (tecovirimat), for the treatment of smallpox, a deadly bioterrorism threat that cannot be addressed through vaccines alone. SIGA has worked closely with the U.S. Government during the development of TPOXX® and has been awarded more than $1.1 billion in procurement and development contracts by the Biomedical Advanced Research and Development Authority of the U.S. Government (BARDA). Most recently, SIGA was awarded in a BARDA contract in excess of $600 million for the maintenance of 1.7 million courses of smallpox antiviral in the strategic national stockpile. SIGA is developing an intravenous formulation of TPOXX and pursuing product and market expansion opportunities including a pediatric formulation, post-exposure prophylaxis indication, and international sales.